Information Provided By:
Fly News Breaks for April 18, 2019
TXMD
Apr 18, 2019 | 07:17 EDT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on TherapeuticsMD with a $27 price target after the company announced yesterday that it has launched Bijuva and signed a binding commitment letter for a $300M term loan. The analyst says both announcements underscore her positive investment thesis and belief that the peak sales potential for Imvexxy, Bijuva and Annovera are all underappreciated.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.